Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin.

ABSTRACT:

Background

Long-term sequelae of acute pulmonary embolism (PE) include decreased quality of life (QoL). Evidence suggests that adequacy of initial anticoagulant treatment in the acute phase of venous thrombosis has a key impact on late postthrombotic complications. We hypothesize that patients with acute PE treated with edoxaban for acute PE experience have improved QoL compared to those treated with warfarin.

Methods

Patients with PE who participated in the Hokusai-VTE trial were contacted between June 2017 and September 2020 for a single long-term follow-up visit. Main outcomes were the generic and disease-specific QoL measured by the 36-Item Short Form Health Survey (SF-36) and Pulmonary Embolism Quality of Life questionnaire.

Results

We included 251 patients from

SUBMITTER: Bavalia R 

PROVIDER: S-EPMC8279124 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature